- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Inovio Pharmaceuticals Faces Lawsuit Deadline
Rosen Law Firm urges investors to act before final deadline in class action case.
Apr. 6, 2026 at 10:10am
Got story updates? Submit your updates here. ›
Inovio Pharmaceuticals Inc., a biotechnology company focused on developing DNA medicines, is facing a final deadline for a class action lawsuit filed by the Rosen Law Firm. The lawsuit alleges that Inovio made false and misleading statements about the development and regulatory status of its COVID-19 vaccine candidate, INO-4800.
Why it matters
The outcome of this lawsuit could have significant financial and reputational implications for Inovio, a company that has been at the forefront of COVID-19 vaccine development. The case highlights the legal risks and scrutiny faced by pharmaceutical companies during the pandemic.
The details
The Rosen Law Firm, a global investor rights law firm, is urging Inovio investors to act before the final deadline to join the class action lawsuit. The lawsuit alleges that Inovio made false and misleading statements about the progress of its COVID-19 vaccine candidate, INO-4800, including claims about the vaccine's regulatory status and development timeline.
- The class action lawsuit was filed in April 2021.
- The final deadline for investors to join the lawsuit is April 6, 2026.
The players
Inovio Pharmaceuticals Inc.
A biotechnology company focused on developing DNA medicines, including a COVID-19 vaccine candidate called INO-4800.
Rosen Law Firm
A global investor rights law firm that has filed a class action lawsuit against Inovio Pharmaceuticals.
What they’re saying
“We encourage investors with large financial interests to contact us directly to participate in the lead plaintiff motion.”
— Laurence Rosen, Founding Partner, Rosen Law Firm
What’s next
The judge in the case will decide on the lead plaintiff motion before the final deadline on April 6, 2026.
The takeaway
This lawsuit highlights the legal risks and scrutiny faced by pharmaceutical companies during the COVID-19 pandemic, especially around the development and regulatory status of vaccine candidates. The outcome could have significant financial and reputational implications for Inovio.
